PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies

Tissue Antigens

Volumn 69, Issue 1, 2007, Pages 19-27

  Sun, J ^a   Xu, K ^b   Wu, C ^a   Wang, Y ^a   Hu, Y ^a   Zhu, Y ^a   Chen, Y ^a   Shi, Q ^a   Yu, G ^a   Zhang, X ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Monoclonal antibody; PD L1

Indexed keywords

B7 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E10; MONOCLONAL ANTIBODY 2H11; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CARCINOMA; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 33845865002     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00701.x     Document Type: Article

References (29)

1. Janeway CA Jr., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994: 76: 75-85.
2. Bugeon L, Dallman MJ. Costimulation of T cells. Am J Respir Crit Care Med 2000: 162: 164-8.
3. Chambers CA, Allision JP. Co-stimulation in T cell response. Curr Opin Immunol 1997: 9: 396-404.
4. Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999: 5: 1365-9.
5. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002: 169: 5538-45.
6. Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death - 1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003: 170: 1257-66.
7. Dong H, Strome SE, Matteson EL et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003: 111: 363-70.
8. Eppihimer MJ, Gunn J, Freeman GJ et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002: 9: 133-45.
9. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001: 2: 261-8.
10. + T cell activation and cytolysis. Eur J Immunol 2003: 33: 3117-26.
11. Freeman GL, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000: 192: 1027-34.
12. + T cells and is overcame by IL-2. Eur J Immunol 2002: 32: 634-43.
13. Latchman YE, Liang SC, Wu Y et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004: 101: 10691-6.
14. Dong H, Zhu G, Tamada K et al. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004: 20: 327-36.
15. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002: 20: 29-53.
16. Tseng SY, Otsuji M, Gorski K et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001: 193: 839-46.
17. Wang S, Bajorath J, Flies DB et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 2003: 197: 1083-91.
18. Liu X, Gao JX, Wen J et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003: 197: 1721-30.
19. Dong H, Strome S, Celis E et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002: 8: 793-800.
20. Iwai Y, Ishida M, Minato N et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002: 99: 12293-7.
21. Zhou ZH, Wang IF, Wang YD et al. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma 1999: 18: 471-8.
22. Wang Q, Chen Y, Ge Y et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signaling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 2004: 64: 566-74.
23. Liang SC, Latchman YE, Buhlmann JE et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003: 33: 2706-16.
24. Wintterle S, Schreiner B, Mitsdoefffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003: 63: 7462-7.
25. Strome SE, Dong H, Tamura H et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003: 63: 6501-5.
26. Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005: 11: 2947-53.
27. Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004: 10: 5094-100.
28. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006: 66: 3381-5.
29. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004: 101: 17174-9.